Skip to main content
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. — Investor Relations & Filings

Ticker · SGMT ISIN · US7867001049 LEI · 2549002OT2F8BV0VPD02 US Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US SGMT

About Sagimet Biosciences Inc.

https://sagimet.com/

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors. These therapeutics are designed to target dysfunctional metabolic and fibrotic pathways resulting from the overproduction of the fatty acid, palmitate. The company's lead product candidate is denifanstat, and its pipeline includes TVB-3567. Sagimet is exploring the application of its FASN inhibitors in treating diseases where dysregulation of fatty acid metabolism plays a key role, such as metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 75% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, dated May 28, 2026, and covers Item 5.02 which describes compensatory option and PSU awards to the company’s officers. It does not present financial statements (so not an IR or 10-K), is not an earnings release, call transcript, or proxy statement, nor is it announcing an exchange delisting, dividend, share buyback, or M&A. It also does not report a change in board membership or an insider share transaction; it solely reports officer compensation awards. As it does not fit any of the specialized categories, it falls into the general “Regulatory Filings” fallback category.
2026-06-03 English
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K current report announcing that Sagimet Biosciences has issued a press release with its quarterly financial results (Item 2.02) and furnishing it as Exhibit 99.1. The actual earnings data aren’t included in the text – it simply states that the press release is attached. Under the “menu vs meal” rule, this is an announcement that a report (the press release) has been published/furnished rather than the report itself. Therefore it should be classified as a Report Publication Announcement (RPA).
2026-05-12 English
10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwritten offering of shares, detailing the underwriting agreement, the offering size, price, and use of proceeds. It also includes exhibits such as the underwriting agreement and legal opinions. This type of filing is a capital/financing update rather than a full financial report or earnings release. The document length is 6450 characters, which is sufficient to contain substantive information about the financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-04-28 English
424B5 - Sagimet Biosciences Inc. (0001400118) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement and accompanying prospectus related to a public offering of Series A common stock by Sagimet Biosciences Inc. It includes information about the offering size, underwriting, risk factors, use of proceeds, dividend policy, and detailed descriptions of the securities offered. The document is filed pursuant to Rule 424(b)(5), which is a SEC rule for prospectus supplements related to securities offerings. The content focuses on the capital raising activity and the terms of the stock offering, not on financial results, management changes, or other report types. Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a full prospectus supplement, supporting high confidence in this classification.
2026-04-28 English
8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2026, for Sagimet Biosciences Inc. It includes an updated investor presentation attached as Exhibit 99.1. The text explicitly states that the presentation is being furnished and is not considered "filed" for certain regulatory purposes. The document is relatively short (4370 characters) and primarily serves to announce the furnishing of an updated investor presentation rather than containing the presentation itself or detailed financial data. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report (Form 8-K) providing regulatory disclosure and furnishing an investor presentation, not the presentation itself or a full financial report. The document does not contain substantive financial statements or detailed analysis, so it is not an Interim Report or Annual Report. It is not a report publication announcement since it includes the presentation as an exhibit rather than just announcing its availability. Therefore, the best fit is Regulatory Filings (RNS).
2026-04-27 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.